LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Heldstab, Jaimie"
  2. AU="Shultz, Tamar"

Search results

Result 1 - 6 of total 6

Search options

  1. Article: ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.

    Stecklein, Shane R / Kimler, Bruce F / Yoder, Rachel / Schwensen, Kelsey / Staley, Joshua M / Khan, Qamar J / O'Dea, Anne P / Nye, Lauren E / Elia, Manana / Heldstab, Jaimie / Home, Trisha / Hyter, Stephen / Isakova, Kamilla / Pathak, Harsh B / Godwin, Andrew K / Sharma, Priyanka

    NPJ breast cancer

    2023  Volume 9, Issue 1, Page(s) 10

    Abstract: Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future ... ...

    Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to investigate the impact of circulating tumor DNA (ctDNA) status and residual cancer burden (RCB) class on outcomes in TNBC patients with RD. We analyze end-of-treatment ctDNA status in 80 TNBC patients with residual disease who are enrolled in a prospective multisite registry. Among 80 patients, 33% are ctDNA positive (ctDNA+) and RCB class distribution is RCB-I = 26%, RCB-II = 49%, RCB-III = 18% and 7% unknown. ctDNA status is associated with RCB status, with 14%, 31%, and 57% of patients within RCB-I, -II, and -III classes demonstrating ctDNA+ status (P = 0.028). ctDNA+ status is associated with inferior 3-year EFS (48% vs. 82%, P < 0.001) and OS (50% vs. 86%, P = 0.002). ctDNA+ status predicts inferior 3-year EFS among RCB-II patients (65% vs. 87%, P = 0.044) and shows a trend for inferior EFS among RCB-III patients (13% vs. 40%, P = 0.081). On multivariate analysis accounting for T stage and nodal status, RCB class and ctDNA status independently predict EFS (HR = 5.16, P = 0.016 for RCB class; HR = 3.71, P = 0.020 for ctDNA status). End-of-treatment ctDNA is detectable in one-third of TNBC patients with residual disease after NAST. ctDNA status and RCB are independently prognostic in this setting.
    Language English
    Publishing date 2023-03-06
    Publishing country United States
    Document type Journal Article
    ISSN 2374-4677
    ISSN 2374-4677
    DOI 10.1038/s41523-023-00512-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.

    Bhatti, Sajjad / Heldstab, Jaimie / Lehn, Carolyn / Tawfik, Ossama / Ash, Ryan M / Hout, David R / Seitz, Rob S / Bailey, Daniel B / O'Dea, Anne P / Jensen, Roy A / Fan, Fang / Khan, Qamar J / Godwin, Andrew K / Sharma, Priyanka

    JCO precision oncology

    2021  Volume 1, Page(s) 1–6

    Language English
    Publishing date 2021-12-31
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.17.00032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.

    Sharma, Priyanka / Abramson, Vandana G / O'Dea, Anne / Nye, Lauren / Mayer, Ingrid / Pathak, Harsh B / Hoffmann, Marc / Stecklein, Shane R / Elia, Manana / Lewis, Sharon / Scott, Jecinta / De Jong, Jilliann A / Wang, Yen Y / Yoder, Rachel / Schwensen, Kelsey / Finke, Karissa / Heldstab, Jaimie / LaFaver, Stephanie / Williamson, Stephen K /
    Phadnis, Milind A / Reed, Gregory A / Kimler, Bruce F / Khan, Qamar J / Godwin, Andrew K

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2021  Volume 27, Issue 14, Page(s) 3896–3904

    Abstract: Purpose: PIK3CA: Patients and methods: Eligible patients had HER2-negative MBC with any number of prior chemotherapies. Phase I was 3+3 dose-escalation design with three dose levels of alpelisib (250, 300, and 350 mg) daily plus nab-paclitaxel 100 mg/ ...

    Abstract Purpose: PIK3CA
    Patients and methods: Eligible patients had HER2-negative MBC with any number of prior chemotherapies. Phase I was 3+3 dose-escalation design with three dose levels of alpelisib (250, 300, and 350 mg) daily plus nab-paclitaxel 100 mg/m
    Results: A total of 43 patients were enrolled (phase I,
    Conclusions: The alpelisib plus nab-paclitaxel combination was well tolerated and shows encouraging efficacy, especially in patients with
    MeSH term(s) Adult ; Aged ; Albumins/administration & dosage ; Biomarkers, Tumor/blood ; Breast Neoplasms/chemistry ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/genetics ; Drug Combinations ; Female ; Humans ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Paclitaxel/administration & dosage ; Receptor, ErbB-2/analysis ; Thiazoles/administration & dosage
    Chemical Substances 130-nm albumin-bound paclitaxel ; Albumins ; Biomarkers, Tumor ; Drug Combinations ; Thiazoles ; Alpelisib (08W5N2C97Q) ; Class I Phosphatidylinositol 3-Kinases (EC 2.7.1.137) ; PIK3CA protein, human (EC 2.7.1.137) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2021-02-18
    Publishing country United States
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-20-4879
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).

    Sharma, Priyanka / Kimler, Bruce F / O'Dea, Anne / Nye, Lauren / Wang, Yen Y / Yoder, Rachel / Staley, Joshua M / Prochaska, Lindsey / Wagner, Jamie / Amin, Amanda L / Larson, Kelsey / Balanoff, Christa / Elia, Manana / Crane, Gregory / Madhusudhana, Sheshadri / Hoffmann, Marc / Sheehan, Maureen / Rodriguez, Roberto / Finke, Karissa /
    Shah, Rajvi / Satelli, Deepti / Shrestha, Anuj / Beck, Larry / McKittrick, Richard / Pluenneke, Robert / Raja, Vinay / Beeki, Venkatadri / Corum, Larry / Heldstab, Jaimie / LaFaver, Stephanie / Prager, Micki / Phadnis, Milind / Mudaranthakam, Dinesh Pal / Jensen, Roy A / Godwin, Andrew K / Salgado, Roberto / Mehta, Kathan / Khan, Qamar

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2020  Volume 27, Issue 4, Page(s) 975–982

    Abstract: Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite ... ...

    Abstract Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens.
    Patients and methods: Patients aged ≥18 years with stage I-III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B). Stromal tumor-infiltrating lymphocytes (sTIL) were assessed. Primary endpoint was pCR in breast and axilla. Other endpoints included residual cancer burden (RCB), toxicity, cost, and event-free (EFS) and overall survival (OS).
    Results: One hundred patients were randomized; arm A (
    Conclusions: The two-drug CbD regimen yielded pCR, RCB 0+I, and survival rates similar to the four-drug regimen of CbP → AC, but with a more favorable toxicity profile and lower treatment-associated cost.
    MeSH term(s) Adult ; Aged ; Anthracyclines/administration & dosage ; Anthracyclines/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Female ; Humans ; Mastectomy ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Neoplasm, Residual ; Progression-Free Survival ; Triple Negative Breast Neoplasms/diagnosis ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/therapy
    Chemical Substances Anthracyclines ; Carboplatin (BG3F62OND5)
    Language English
    Publishing date 2020-11-18
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-20-3646
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.

    Sharma, Priyanka / López-Tarruella, Sara / García-Saenz, José Angel / Khan, Qamar J / Gómez, Henry L / Prat, Aleix / Moreno, Fernando / Jerez-Gilarranz, Yolanda / Barnadas, Agustí / Picornell, Antoni C / Monte-Millán, María Del / González-Rivera, Milagros / Massarrah, Tatiana / Pelaez-Lorenzo, Beatriz / Palomero, María Isabel / González Del Val, Ricardo / Cortés, Javier / Fuentes-Rivera, Hugo / Morales, Denisse Bretel /
    Márquez-Rodas, Iván / Perou, Charles M / Lehn, Carolyn / Wang, Yen Y / Klemp, Jennifer R / Mammen, Joshua V / Wagner, Jamie L / Amin, Amanda L / O'Dea, Anne P / Heldstab, Jaimie / Jensen, Roy A / Kimler, Bruce F / Godwin, Andrew K / Martín, Miguel

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2018  Volume 24, Issue 23, Page(s) 5820–5829

    Abstract: Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report ... ...

    Abstract Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC.
    Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m
    Results: Median age was 51 years, and 52% were node-positive. pCR and RCB I rates were 55% and 13%, respectively. Five percent of pCR patients, 0% of RCB I patients, and 58% of RCB II/III patients received adjuvant anthracyclines. Three-year RFS and OS were 79% and 87%, respectively. Three-year RFS was 90% in patients with pCR and 66% in those without pCR [HR = 0.30; 95% confidence interval (CI), 0.14-0.62;
    Conclusions: Neoadjuvant carboplatin plus docetaxel yields encouraging efficacy in TNBC. Patients achieving pCR or RCB I with this regimen demonstrate excellent 3-year RFS and OS without adjuvant anthracycline.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Carboplatin/administration & dosage ; Combined Modality Therapy ; Docetaxel/administration & dosage ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Treatment Outcome ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/pathology
    Chemical Substances Biomarkers, Tumor ; Docetaxel (15H5577CQD) ; Carboplatin (BG3F62OND5)
    Language English
    Publishing date 2018-07-30
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-18-0585
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

    Sharma, Priyanka / López-Tarruella, Sara / García-Saenz, Jose Angel / Ward, Claire / Connor, Carol S / Gómez, Henry L / Prat, Aleix / Moreno, Fernando / Jerez-Gilarranz, Yolanda / Barnadas, Augusti / Picornell, Antoni C / Del Monte-Millán, Maria / Gonzalez-Rivera, Milagros / Massarrah, Tatiana / Pelaez-Lorenzo, Beatriz / Palomero, María Isabel / González Del Val, Ricardo / Cortes, Javier / Fuentes Rivera, Hugo /
    Bretel Morales, Denisse / Márquez-Rodas, Iván / Perou, Charles M / Wagner, Jamie L / Mammen, Joshua M V / McGinness, Marilee K / Klemp, Jennifer R / Amin, Amanda L / Fabian, Carol J / Heldstab, Jaimie / Godwin, Andrew K / Jensen, Roy A / Kimler, Bruce F / Khan, Qamar J / Martin, Miguel

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2017  Volume 23, Issue 3, Page(s) 649–657

    Abstract: Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum ... ...

    Abstract Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC.
    Experimental design: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA chemotherapy regimen of carboplatin (AUC 6) + docetaxel (75 mg/m
    Results: Among 190 patients, median tumor size was 35 mm, 52% were lymph node positive, and 16% had germline BRCA1/2 mutation. The overall pCR and RCB 0 + 1 rates were 55% and 68%, respectively. pCRs in patients with BRCA-associated and wild-type TNBC were 59% and 56%, respectively (P = 0.83). On multivariable analysis, stage III disease was the only factor associated with a lower likelihood of achieving a pCR. Twenty-one percent and 7% of patients, respectively, experienced at least one grade 3 or 4 adverse event.
    Conclusions: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA-associated and wild-type TNBC. These results are comparable with pCR achieved with the addition of carboplatin to anthracycline-taxane chemotherapy. Our study adds to the existing data on the efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in randomized studies. Clin Cancer Res; 23(3); 649-57. ©2016 AACR.
    Language English
    Publishing date 2017-02-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-16-0162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top